WHO ICTRP trial
A first-in-human, randomized, dose-Escalation, double-blind, placebo-controlled…
NL-OMON46244 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON46244 |
|---|---|
| Public title | A first-in-human, randomized, dose-Escalation, double-blind, placebo-controlled study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects. |
| Scientific title | A first-in-human, randomized, dose-Escalation, double-blind, placebo-controlled study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects. - APX001 First in human study. |
| Primary sponsor | Amplyx Pharmaceuticals, Inc. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | Fungal diseases.;10003816;Fungal diseases. |
| Interventions | SAD: Cohort 1: 1 x 10 mg Cohort 2: 1 x 30 mg Cohort 3: 1 x 100 mg Cohort 4: 1 x 300 mg Cohort 5: 1 x 525 mg Cohort 6: 1 x 800 mg MAD: Cohort 7: 1 x 50 mg Cohort 8: tbd x tbc mg Cohort 9: tbc x tbc mg Cohort 10: tbc x tbc mg Cohort 11: tbd… |
| Registration date | Apr 11, 2017 |
| Target size | 120 |
| Secondary IDs | 2016-000974-39;NL57571.056.16 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: